Merck & Co., Inc. (MRK)
NYSE: MRK · Pharmaceuticals · Rahway, NJ
Our rating: Neutral
Call changed from Cautious to Neutral at $146.94, moderate conviction, November 5, 2026.
Breaks if: The Neutral call moves toward Cautious if free cash flow for two consecutive reporting periods annualizes below $10B — signaling the gap between reported net income and actual cash generation is structural rather than transitory — or if full-year reported revenue growth turns negative in the next annual filing. It moves toward Positive if reported year-over-year revenue growth surpasses 6% in any of the next four quarters, indicating the pipeline is delivering meaningful top-line contribution and justifying the current premium to sector norms.
Key figures
| Market value | $329.7B |
|---|---|
| Revenue, last 12 months | $67.4B |
| Net income, last 12 months | $2.5B |
| Free cash flow, last 12 months | $14.7B |
| Price to earnings | 134.4× |
| Free cash flow yield | 4.5% |
| Dividend yield | 2.5% |
| Operating margin | n/a |
| Return on equity | 5.1% |
| Beta to the S&P 500 | 0.29 |
| Volatility, annualized | 28.8% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $18.1B | 4.7% | $2.04 | $5.5B |
| June 30, 2026 | $16.6B | 5.1% | $-0.54 | $4.5B |
| March 31, 2026 | $16.3B | 4.9% | $-1.72 | $2.9B |
| December 31, 2025 | $16.4B | 5.0% | $1.20 | $1.8B |
| September 30, 2025 | $17.3B | 3.7% | $2.32 | $6.8B |
| June 30, 2025 | $15.8B | −1.9% | $1.76 | $2.5B |
| March 31, 2025 | $15.5B | −1.6% | $2.01 | $1.2B |
| December 31, 2024 | $15.6B | 6.8% | $1.48 | $2.5B |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $17.2B: Claude 62%, Gemini 93%, Mistral 78%
- Diluted earnings per share are at least $1.20: Claude 55%, Gemini 75%, Mistral 68%
- Free cash flow for the quarter is at least $1.82B: Claude 60%, Gemini 96%, Mistral 85%
23 ledger entries and 19 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.